{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:31:18Z","timestamp":1754152278742,"version":"3.41.2"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jneuroim.2025.578672","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T01:00:30Z","timestamp":1750208430000},"page":"578672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Serum levels of tumor necrosis factor and TNFRSF1A gene polymorphisms in Egyptian multiple sclerosis patients: the influence on susceptibility and severity"],"prefix":"10.1016","volume":"406","author":[{"given":"Maged Abdel","family":"Naseer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montasser","family":"Hegazy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim M.","family":"El-Mehdawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Shawky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr Mohamed","family":"Fouad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2025.578672_bb0005","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jneuroim.2015.10.003","article-title":"Molecular dynamics and intracellular signaling of the TNF-R1 with the R92Q mutation","volume":"289","author":"Agull\u00f3","year":"2015","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578672_bb0010","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"The lenercept multiple sclerosis study group and the University of British Columbia MS\/MRI analysis group. TNF neutralisation in MS: results of a randomised. Placebo controlled multicentre study","volume":"53","author":"Arnason","year":"1999","journal-title":"Neurology"},{"issue":"51","key":"10.1016\/j.jneuroim.2025.578672_bb0015","doi-asserted-by":"crossref","first-page":"13051","DOI":"10.1073\/pnas.1807499115","article-title":"Intrinsic TNFR2 signaling in T regulatory cells provides protection in CNS autoimmunity","volume":"115","author":"Atretkhany","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.jneuroim.2025.578672_bb0020","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.tig.2017.09.004","article-title":"The genetics of multiple sclerosis: from 0 to 200 in 50 years","volume":"33","author":"Baranzini","year":"2017","journal-title":"Trends Genet."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578672_bb0025","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/hmg\/ddn388","article-title":"Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis","volume":"18","author":"Baranzini","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jneuroim.2025.578672_bb0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jneuroim.2015.03.015","article-title":"GWAS-identified multiple sclerosis risk loci involved in immune response: validation in Russians","volume":"282","author":"Bashinskaya","year":"2015","journal-title":"J. Neuroimmunol."},{"year":"2013","series-title":"Analysis of Immune-Related Loci Identifies 48 New Susceptibility Variants for Multiple Sclerosis","author":"Beechham","key":"10.1016\/j.jneuroim.2025.578672_bb0035"},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578672_bb0040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1128\/jcm.28.3.495-503.1990","article-title":"Rapid and simple method for purification of nucleic acids","volume":"28","author":"Boom","year":"1990","journal-title":"J. Clin. Microbiol."},{"issue":"8","key":"10.1016\/j.jneuroim.2025.578672_bb0045","article-title":"Genome-wide association study of severity in multiple sclerosis","volume":"12","author":"Briggs","year":"2011","journal-title":"Genes & Immunity"},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2025.578672_bb0050","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jneuroim.2010.01.003","article-title":"MGAT5 alters the severity of multiple sclerosis","volume":"220","author":"Brynedal","year":"2010","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578672_bb0055","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2249.2011.04484.x","article-title":"Role of tumour necrosis factor (TNF)-\u03b1 and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis","volume":"166","author":"Caminero","year":"2011","journal-title":"Clinical & Experimental Immunology"},{"issue":"22","key":"10.1016\/j.jneuroim.2025.578672_bb0060","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1212\/WNL.0b013e318294b2d6","article-title":"TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis","volume":"80","author":"Comabella","year":"2013","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2025.578672_bb0065","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0022-1759(94)90156-2","article-title":"Tumor necrosis factor (TNF) \u03b1 quantification by ELISA and bioassay: effects of TNF\u03b1-soluble TNF receptor (p55) complex dissociation during assay incubations","volume":"177","author":"Corti","year":"1994","journal-title":"J. Immunol. Methods"},{"issue":"7","key":"10.1016\/j.jneuroim.2025.578672_bb0070","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/ng.401","article-title":"Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci","volume":"41","author":"De Jager","year":"2009","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578672_bb0075","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1152\/physrev.00045.2017","article-title":"The TNF family of ligands and receptors: communication modules in the immune system and beyond","volume":"99","author":"Dostert","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jneuroim.2025.578672_bib281","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/135245850100700303","article-title":"Similar pro- and anti-inflammatory cytokine production in the different clinical forms of multiple sclerosis","volume":"7","author":"Dur\u00e1n","year":"2001","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2025.578672_bb0080","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419895155","article-title":"PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-\u03b1 therapy-associated demyelinating disorders","volume":"13","author":"Engel","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578672_bb0085","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2249.2003.02053.x","article-title":"Monocyte-derived cytokines in multiple sclerosis","volume":"131","author":"Filion","year":"2003","journal-title":"Clinical & Experimental Immunology"},{"key":"10.1016\/j.jneuroim.2025.578672_bb0090","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3389\/fcell.2020.00401","article-title":"Selective targeting of TNF receptors as a novel therapeutic approach","volume":"8","author":"Fischer","year":"2020","journal-title":"Frontiers in cell and developmental biology"},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578672_bb0095","doi-asserted-by":"crossref","DOI":"10.1177\/20552173231155055","article-title":"New algorithmic approach for easier and faster extended disability status scale calculation","volume":"9","author":"Fouad","year":"2023","journal-title":"Multiple Sclerosis Journal\u2013Experimental, Translational and Clinical"},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578672_bb0100","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3390\/cells9102290","article-title":"Re-examining the role of TNF in MS pathogenesis and therapy","volume":"9","author":"Fresegna","year":"2020","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578672_bb0105","article-title":"Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies","volume":"2","author":"George","year":"2016","journal-title":"Neurology: Genetics"},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578672_bb0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.nrleng.2022.07.002","article-title":"Variant rs4149584 (R92Q) of the TNFRSF1A gene in patients with familial multiple sclerosis","volume":"40","author":"Gomez-Pinedo","year":"2022","journal-title":"Neurolog\u00eda\u00a0 (English edition)"},{"issue":"7412","key":"10.1016\/j.jneuroim.2025.578672_bb0115","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nature11307","article-title":"TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis","volume":"488","author":"Gregory","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578672_bb0120","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","article-title":"The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor","volume":"83","author":"Grell","year":"1995","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578672_bb0125","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/iji.12183","article-title":"Association of TNFAIP 3 and TNFRSF 1 A variation with multiple sclerosis in a German case\u2013control cohort","volume":"42","author":"Hoffjan","year":"2015","journal-title":"Int. J. Immunogenet."},{"issue":"291","key":"10.1016\/j.jneuroim.2025.578672_bb0130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa9223","article-title":"Genetic variants associated with autoimmunity drive NF\u03baB signaling and responses to inflammatory stimuli","volume":"7","author":"Housley","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578672_bb0135","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H","article-title":"TNF\u03b1 and the TNF receptor superfamily: structure-function relationship (s)","volume":"50","author":"Idriss","year":"2000","journal-title":"Microsc. Res. Tech."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578672_bb0140","article-title":"The genetic association of variants in CD6, TNFRSF1A and IRF8 to multiple sclerosis: a multicenter case-control study","volume":"6","author":"International Multiple Sclerosis Genetics Consortium","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.jneuroim.2025.578672_bb0145","article-title":"The multiple sclerosis genomic map: role of peripheral immune cells and resident microglia in susceptibility","author":"International Multiple Sclerosis Genetics Consortium","year":"2017","journal-title":"BioRxiv"},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578672_bb0150","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/brain\/awv078","article-title":"An ImmunoChip study of multiple sclerosis risk in African Americans","volume":"138","author":"Isobe","year":"2015","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578672_bb0155","first-page":"928","article-title":"iRHOM2 is a critical pathogenic mediator of inflammatory arthritis","volume":"123","author":"Issuree","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578672_bb0160","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/gene.2009.81","article-title":"Multiple sclerosis susceptibility alleles in African Americans","volume":"11","author":"Johnson","year":"2010","journal-title":"Genes & Immunity"},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578672_bb0165","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3892\/mmr.2013.1256","article-title":"Cytokine profile in relapsing-remitting multiple sclerosis patients and the association between progression and activity of the disease","volume":"7","author":"Kallaur","year":"2013","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jneuroim.2025.578672_bb0170","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1007\/s12035-016-9846-x","article-title":"Cytokine profile in patients with progressive multiple sclerosis and its association with disease progression and disability","volume":"54","author":"Kallaur","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jneuroim.2025.578672_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS demyelination with TNF-\u03b1 blockers","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578672_bb0180","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/135245850100700302","article-title":"Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease","volume":"7","author":"Killestein","year":"2001","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jneuroim.2025.578672_bb0185","series-title":"Seminars in Immunopathology","first-page":"63","article-title":"Genetics and functional genomics of multiple sclerosis","volume":"vol. 44","author":"Kim","year":"2022"},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2025.578672_bb0190","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0165-5728(00)00396-9","article-title":"Monocytes in multiple sclerosis: phenotype and cytokine profile","volume":"112","author":"Kouwenhoven","year":"2001","journal-title":"J. Neuroimmunol."},{"issue":"10. Vyp. 2","key":"10.1016\/j.jneuroim.2025.578672_bb0195","doi-asserted-by":"crossref","first-page":"10","DOI":"10.17116\/jnevro201611610210-15","article-title":"Association analysis of cytokine receptors\u2019 genes polymorphisms with clinical features of multiple sclerosis","volume":"116","author":"Kulakova","year":"2016","journal-title":"Zh. Nevrol. Psikhiatr. Im. S S Korsakova"},{"issue":"11","key":"10.1016\/j.jneuroim.2025.578672_bb0200","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jneuroim.2025.578672_bb0205","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1093\/rheumatology\/keac665","article-title":"Therapeutic consequences in patients with both inflammatory rheumatic diseases and multiple sclerosis","volume":"62","author":"Letarouilly","year":"2023","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578672_bb0210","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1352458513496882","article-title":"Association between multiple sclerosis risk-associated SNPs and relapse and disability\u2013a prospective cohort study","volume":"20","author":"Lin","year":"2014","journal-title":"Mult. Scler. J."},{"issue":"18","key":"10.1016\/j.jneuroim.2025.578672_bb0215","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1523\/JNEUROSCI.0211-16.2016","article-title":"Oligodendroglial TNFR2 mediates membrane TNF-dependent repair in experimental autoimmune encephalomyelitis by promoting oligodendrocyte differentiation and remyelination","volume":"36","author":"Madsen","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jneuroim.2025.578672_bb0220","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbi.2019.11.017","article-title":"Oligodendrocytes modulate the immune-inflammatory response in EAE via TNFR2 signaling","volume":"84","author":"Madsen","year":"2020","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578672_bb0225","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-510X(97)00142-1","article-title":"Tumor necrosis factor \u03b1 and its receptors in relapsing-remitting multiple sclerosis","volume":"152","author":"Martino","year":"1997","journal-title":"J. Neurol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2025.578672_bb0230","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0165-5728(96)00032-X","article-title":"Multiple sclerosis: the proinflammatory cytokines lymphotoxin-\u03b1 and tumour necrosis factor-\u03b1 are upregulated in cerebrospinal fluid mononuclear cells","volume":"66","author":"Matusevicius","year":"1996","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578672_bb0235","first-page":"101","article-title":"Management of multiple sclerosis","volume":"39","author":"Naser","year":"2023","journal-title":"Management"},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578672_bb0240","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/brain\/119.1.213","article-title":"Augmented expression of tumour necrosis factor-\u03b1 and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis","volume":"119","author":"Navikas","year":"1996","journal-title":"Brain"},{"issue":"22","key":"10.1016\/j.jneuroim.2025.578672_bb0245","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1212\/01.wnl.0000436612.66328.8a","article-title":"Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus","volume":"81","author":"Ottoboni","year":"2013","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jneuroim.2025.578672_bb0250","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/jnnp-2016-313722","article-title":"Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study","volume":"87","author":"Pan","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578672_bb0255","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/ana.22609","article-title":"Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci","volume":"70","author":"Patsopoulos, N.A., Bayer Pharma MS Genetics Working Group, the Steering Committees of Studies Evaluating IFN\u03b2-1b and a CCR1-Antagonist, ANZgene Consortium, GeneMSA, International Multiple Sclerosis Genetics Consortium and de Bakker, P.I","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578672_bb0260","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.neuroscience.2015.06.038","article-title":"TNF and its receptors in the CNS: the essential, the desirable and the deleterious effects","volume":"302","author":"Probert","year":"2015","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578672_bb0265","doi-asserted-by":"crossref","first-page":"721","DOI":"10.4049\/jimmunol.176.2.721","article-title":"Cutting edge: tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation","volume":"176","author":"Smookler","year":"2006","journal-title":"J. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2025.578672_bb0270","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jneuroim.2010.03.020","article-title":"Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain","volume":"223","author":"Swaminathan","year":"2010","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578672_bb0275","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"The Lancet Neurology"},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578672_bb0280","article-title":"Tumor necrosis factor alpha blockade and multiple sclerosis: exploring new avenues","volume":"13","author":"Zahid","year":"2021","journal-title":"Cureus"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825001535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825001535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T21:54:20Z","timestamp":1753134860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572825001535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":57,"alternative-id":["S0165572825001535"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578672","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum levels of tumor necrosis factor and TNFRSF1A gene polymorphisms in Egyptian multiple sclerosis patients: the influence on susceptibility and severity","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578672","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"578672"}}